Roles of programmed cell death protein 5 in inflammation and cancer (Review)

被引:19
|
作者
Wang, Wei [1 ]
Song, Xiao-Wen [1 ]
Zhao, Cheng-Hai [1 ]
机构
[1] China Med Univ, Dept Pathophysiol, Coll Basic Med Sci, Shenyang 110122, Liaoning, Peoples R China
关键词
programmed cell death 5; inflammation; cancer; p53; P-glycoprotein; CISPLATIN-INDUCED APOPTOSIS; IN-VITRO; CELL-DEATH-5; PROTEIN; REDUCED EXPRESSION; DISEASE-ACTIVITY; SYNOVIAL-FLUID; ANTITUMOR ROLE; PDCD5; GENE; INVOLVEMENT;
D O I
10.3892/ijo.2016.3706
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PDCD5 (programmed cell death 5) is an apoptosis related gene cloned in 1999 from a human leukemic cell line. PDCD5 protein containing 125 amino acid (aa) residues sharing significant homology to the corresponding proteins of species. Decreased expression of PDCD5 has been found in many human tumors, including breast, gastric cancer, astrocytic glioma, chronic myelogenous leukemia and hepatocellular carcinoma. In recent years, increased number of studies have shown the functions and mechanisms of PDCD5 protein in cancer cells, such as paraptosis, cell cycle and immunoregulation. In the present review, we provide a comprehensive review on the role of PDCD5 in cancer tissues and cells. This review summarizes the recent studies of the roles of PDCD5 in inflammation and cancer. We mainly focus on discoveries related to molecular mechanisms of PDCD5 protein. We also discuss some discrepancies between the current studies. Overall, the current available data will open new perspectives for a better understanding of PDCD5 in cancer.
引用
收藏
页码:1801 / 1806
页数:6
相关论文
共 50 条
  • [1] Ceramides and their roles in programmed cell death
    Pilatova, Martina Bago
    Solarova, Zuzana
    Mezencev, Roman
    Solar, Peter
    ADVANCES IN MEDICAL SCIENCES, 2023, 68 (02): : 417 - 425
  • [2] Programmed cell death 4 protein in esophageal cancer
    Fassan, Matteo
    Cagol, Matteo
    Pennelli, Gianmaria
    Rizzetto, Christian
    Giacomelli, Luciano
    Battaglia, Giorgio
    Zaninotto, Giovanni
    Ancona, Ermanno
    Ruol, Alberto
    Rugge, Massimo
    ONCOLOGY REPORTS, 2010, 24 (01) : 135 - 139
  • [3] Programmed cell death protein 1 in cancer cells
    Chunlian Wei
    Meijun Liu
    Weifen Zhang
    Cell Communication and Signaling, 23 (1)
  • [4] Nobiletin as an inducer of programmed cell death in cancer: a review
    Jun Huang
    Zaoshang Chang
    Quzhe Lu
    Xuedong Chen
    Masoud Najafi
    Apoptosis, 2022, 27 : 297 - 310
  • [6] Nobiletin as an inducer of programmed cell death in cancer: a review
    Huang, Jun
    Chang, Zaoshang
    Lu, Quzhe
    Chen, Xuedong
    Najafi, Masoud
    APOPTOSIS, 2022, 27 (5-6) : 297 - 310
  • [7] Roles of the tumor microenvironment in the resistance to programmed cell death protein 1 inhibitors in patients with gastric cancer
    Xia, Ren-Jie
    Du, Xiao-Yu
    Shen, Li-Wen
    Ma, Jian-Guo
    Xu, Shu-Mei
    Fan, Rui-Fang
    Qin, Jian-Wei
    Yan, Long
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 16 (09)
  • [8] Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review
    Choi, Franchesca D.
    Kraus, Christina N.
    Elsensohn, Ashley N.
    Carley, Sama K.
    Lehmer, Larisa M.
    Nguyen, Rebecca T.
    Linden, Kenneth G.
    Shiu, Jessica
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) : 440 - 459
  • [9] Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis
    Ouyang, L.
    Shi, Z.
    Zhao, S.
    Wang, F. -T.
    Zhou, T. -T.
    Liu, B.
    Bao, J. -K.
    CELL PROLIFERATION, 2012, 45 (06) : 487 - 498
  • [10] Prognostic roles of hematological indicators in programmed cell death protein 1/programmed cell death ligand 1 inhibitors for small-cell lung cancer: a retrospective cohort study
    Du, Jiya
    Zhang, Qian
    Tian, Le
    Chen, Yishan
    Tian, Ye
    Dempke, Wolfram C. M.
    Arasanz, Hugo
    Soo, Ross Andrew
    Zhou, Zhiguo
    Meng, Qingju
    Liu, Yibing
    JOURNAL OF THORACIC DISEASE, 2024, 16 (12) : 8669 - 8683